100 related articles for article (PubMed ID: 23176004)
1. First-line erlotinib inferior to chemo in advanced lung cancer.
Oncology (Williston Park); 2012 Oct; 26(10):930-1. PubMed ID: 23176004
[No Abstract] [Full Text] [Related]
2. Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer.
Hotta K; Kiura K
Expert Rev Anticancer Ther; 2011 Jul; 11(7):991-7. PubMed ID: 21806322
[TBL] [Abstract][Full Text] [Related]
3. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
[TBL] [Abstract][Full Text] [Related]
4. [Perspectives and future developments of epidermal growth factor receptors inhibitors].
Soria JC
Rev Pneumol Clin; 2007 Jan; 63(1 Pt 2):2S18-20. PubMed ID: 17242641
[No Abstract] [Full Text] [Related]
5. Erlotinib in previously treated non-small-cell lung cancer.
Shepherd FA; Rodrigues Pereira J; Ciuleanu T; Tan EH; Hirsh V; Thongprasert S; Campos D; Maoleekoonpiroj S; Smylie M; Martins R; van Kooten M; Dediu M; Findlay B; Tu D; Johnston D; Bezjak A; Clark G; Santabárbara P; Seymour L;
N Engl J Med; 2005 Jul; 353(2):123-32. PubMed ID: 16014882
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib in the treatment of advanced non-small-cell lung cancer.
Reck M
Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595
[TBL] [Abstract][Full Text] [Related]
7. Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer.
Perez-Soler R
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4589-92. PubMed ID: 17671146
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence.
Carlson JJ
Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):409-16. PubMed ID: 19817524
[TBL] [Abstract][Full Text] [Related]
9. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
Comis RL
Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
[No Abstract] [Full Text] [Related]
10. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ
Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670
[TBL] [Abstract][Full Text] [Related]
11. Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.
Garfield DH
J Clin Oncol; 2005 Oct; 23(30):7738-40. PubMed ID: 16234533
[No Abstract] [Full Text] [Related]
12. Erlotinib in lung cancer.
Nabhan C; Bitran JD
N Engl J Med; 2005 Oct; 353(16):1739-41; author reply 1739-41. PubMed ID: 16236747
[No Abstract] [Full Text] [Related]
13. Targeted therapies for non-small cell lung cancer.
Spicer J; Harper P
Int J Clin Pract; 2005 Sep; 59(9):1055-62. PubMed ID: 16115182
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib in non-small cell lung cancer treatment: current status and future development.
Gridelli C; Bareschino MA; Schettino C; Rossi A; Maione P; Ciardiello F
Oncologist; 2007 Jul; 12(7):840-9. PubMed ID: 17673615
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
Technol Eval Cent Assess Program Exec Summ; 2011 Mar; 25(6):1-5. PubMed ID: 21638942
[No Abstract] [Full Text] [Related]
16. Erlotinib: optimizing therapy with predictors of response?
Goodin S
Clin Cancer Res; 2006 May; 12(10):2961-3. PubMed ID: 16707589
[No Abstract] [Full Text] [Related]
17. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ
J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
Gaafar RM; Surmont VF; Scagliotti GV; Van Klaveren RJ; Papamichael D; Welch JJ; Hasan B; Torri V; van Meerbeeck JP;
Eur J Cancer; 2011 Oct; 47(15):2331-40. PubMed ID: 21802939
[TBL] [Abstract][Full Text] [Related]
20. [Personalized treatment in non-small cell lung cancer].
Campos-Parra AD; Cruz-Rico G; Arrieta O
Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
[No Abstract] [Full Text] [Related]
[Next] [New Search]
